Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04898686
Other study ID # B3002020000086
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2020
Est. completion date August 6, 2021

Study information

Verified date April 2022
Source University Hospital, Antwerp
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

With this double- blind, randomised, placebo-controlled study, the investigators want to investigate the influence of a chewable with the probiotic strain Lacticaseibacillus rhamnosus GG on the symptoms and immunological markers of allergic rhinoconjunctivitis (AR). In addition, the investigators aim to study the influence of this probiotic chewable on the microbiome of the upper respiratory tract after administration in adults with AR. The bacterial and cytokine profiles in the naso- and oropharynx will be monitored before, during and after the treatment.


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date August 6, 2021
Est. primary completion date August 6, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adults aged 18 at the time of registration; - Seasonal allergic rhinoconjunctivitis (AR) in the context of grass pollen allergy diagnosed on the basis of anamnesis cfr. ARIA guidelines and positive skin prick test and / or immunocap assay; - Positive skin prick test (SPT) for grass pollen and / or the presence of specific IgE for grass pollen, confirmed by a medical specialist, measured at the start of the study: Soluprick SQ Phleum pratense pollen 10 HEP - ALK and / or IgE specific immunocap assay Phleum pratense (timothy grass) (g6); - Body Mass Index in the range of 19-32 kg / m2; - Instructed during screening and agreed not to use other probiotic products outside of the study during the study period; - Signed the consent form. Exclusion Criteria: - Antibiotic use at baseline and during the study; - Pregnant women; - Unstable / uncontrolled asthma (to be determined by investigator-physician); - Sensitization to dust mites - History of probiotic use in the past two weeks; - Current diagnosis of cancer or immunosuppressive therapy within the past 6 months; - Abnormalities of the oral mucosa; - Acute and chronic infectious and inflammatory upper airway diseases (eg acute / chronic rhinosinusitis cfr. EPOS guidelines); - Clinically significant bleeding disorder; - Any other medical condition that, in the principal investigator's opinion, warrants exclusion from the trial; - History of regular use (> 3 days out of 7) of tobacco products within the previous two weeks

Study Design


Intervention

Biological:
Probiotic chewables
chewables containing Lacticaseibacillus rhamnosus GG
Placebo chewables
chewables without probiotic strain. Ingredients: Xylitol, microcrystalline cellulose, stearic acid, natural orange flavor, silica, magnesium stearate, citric acid and malic acid.

Locations

Country Name City State
Belgium Antwerp University Hospital Edegem

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Antwerp DSM Nutritional Products, Inc.

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Transfer of L. rhamnosus GG (estimated CFU counts) to the oronasopharyngeal cavity after administration of the chewable qPCR at 8 weeks
Primary Changes in the score of allergic rhinitis symptoms Daily questionnaires will be used, in which a self-reported Total Nasal Symptom Score (TNSS) based on rhinorrhea, nasal congestion, nasal itching and sneezing with symptom severity ranging from 0 (no problem) to 12 (very severe problem) will be recorded. over the study period (= 10 weeks)
Secondary changes in microbiome of the oronasopharyngeal region after administration of the chewable 16S rRNA amplicon sequencing baseline, 8 weeks
Secondary Inlfuence on general nose- and mouth health A clinical evaluation by an ENT specialist will be performed at the start and 8 weeks of the study to assess the general nose and mouth health of the participants. Questions on discomfort and symptoms of inflammation or infection in the nose and mouth will be included in the Sino-Nasal Outcome Test (SNOT-22)-based questionnaire implemented at the start, week 8 and week 10. Symptoms will be scored from 0 (no problem) to 5 (very severe problem) baseline, 8 weeks, 10 weeks
Secondary Changes in the absolute numbers of specific airway pathogens and viruses qPCR baseline, 8 weeks
Secondary Changes in cytokine levels (e.g. IL-10, IL-4, IL-5, IL-13) in oro- and nasopharynx samples, and cytokine and antibody levels in blood samples qPCR and/or ELISA baseline, 8 weeks
Secondary Frequency of medication use Daily questionnaires will be used where the type and frequency of medication use should be recorded over the study period (= 10 weeks)
See also
  Status Clinical Trial Phase
Completed NCT03850626 - Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
Completed NCT03682965 - Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study Phase 2
Completed NCT04541004 - Adolescent Mite Allergy Safety Evaluation Phase 3
Completed NCT02556801 - Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy Phase 2
Completed NCT01966224 - A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects Phase 1
Completed NCT01918956 - PURETHAL Birch RUSH Study Phase 4
Completed NCT01682070 - SUBLIVAC FIX Phleum Pratense DT/DRF Phase 2
Completed NCT01438827 - Avanz Phleum Pratense Maintenance Dose Phase 2/Phase 3
Completed NCT01438463 - PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis Phase 2
Completed NCT00985296 - Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC) N/A
Completed NCT02437786 - Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® Phase 4
Completed NCT01740284 - A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine Phase 3
Completed NCT04912076 - S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen Phase 1
Completed NCT03365648 - Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics N/A
Completed NCT05455749 - Effect of holoBLG on Cat Allergic Patients N/A
Completed NCT01707069 - A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Phase 1
Completed NCT01466465 - Vitamin D and Grass Pollen Specific Immunotherapy Phase 2
Completed NCT01567306 - Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense Phase 2
Completed NCT01490411 - Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis Phase 2
Completed NCT00777374 - Study of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects With Epicutanoeus Allergen Administration Phase 2